Best Hormone therapy for prostate cancer Doctors Worldwide — TOP 44

Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.

• Authored over 40 research publications focusing on tumor biology and immunology.
• Former Head of Internal Diseases at Istanbul Okan University Faculty of Medicine.
• Held leadership roles in medical oncology at GATA Haydarpasa Training Hospital.
• Member of the Turkish Medical Oncology Association and European Head and Neck Society.

Dr. Ilker Tinay is an urological oncologist at Anadolu Medical Center. He sits on the Executive Board of the Association of Urooncology. Dr. Tinay specializes in minimally invasive surgery and neo-bladder reconstruction. He works at Anadolu, a Top 10 global hospital according to MTQUA. The center is also affiliated with Johns Hopkins Medicine.

• Member of the American College of Surgeons and European Association of Urology.
• Secretary of the Bladder Tumours Research Group.
• Winner of the Urooncology Association Scientific Research Award.
• Performs complex procedures including robotic da Vinci prostatectomy and nephrectomy.

Prof. Merimsky leads the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center, with over 41 years of experience specializing in prostate cancer treatments.

• Associate Professor of Oncology at Tel-Aviv University
• Fellowship-trained in sarcoma and bone oncology at Institut Gustave Roussy, Paris
• Active member of ESMO and ASCO with ongoing research contributions
• Former Chairman of the Israeli Society for Oncology and Radiotherapy

Dr. Sarid specializes in hormone therapy for prostate cancer at Sourasky Medical Center, with extensive experience in oncology treatments.

• Senior oncologist at Sourasky Medical Center since 2009
• Trained in cancer urology at Oxford University
• Principal investigator of clinical trials in cancer therapies
• Member of The European Society for Medical Oncology

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Dr. Osama Abdel Mohimen Mohamed leads the Hematology Unit at Shefaa Al Orman Oncology Hospital. He treats complex blood cancers, including leukemia, lymphoma, and myeloma. Dr. Mohamed is a member of the European Society for Medical Oncology. He also holds memberships in the American Society of Hematology and ASBMT.

• Specializes in chemotherapy, immunotherapy, and bone marrow transplantation.
• Manages aggressive acute leukemia and chronic blood disorders.
• Treats complications arising from various solid tumors.
• Works at an ESMO-accredited center that handles 6,000 patients annually.

Prof. Zamboglou leads prostate cancer research at Medical Center University of Freiburg, with accolades from the German Society of Radiation Oncology.

• Board-certified in Radiotherapy and Radiation Oncology
• Head of the section 'Interventional Radiation Oncology'
• Recipient of the Herman-Holthusen Award
• Member of ESTRO-ACROP guideline committee for prostate cancer
• Prostate cancer research group leader at university hospital

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Sinan Karaaslan is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, colorectal, and urogenital system cancers. Dr. Karaaslan brings clinical expertise from major institutions, including Medical Park and Gülhane Military Medical Academy. He works at a hospital affiliated with the Johns Hopkins Hospital.

• Holds personal certification from the European Society for Medical Oncology.
• Treats complex conditions, including stage 4 colon and lung cancers.
• Member of the Turkish Medical Oncology and Turkish Lung Cancer societies.
• Performs systemic therapies such as immunotherapy, targeted therapy, and chemotherapy.

Dr. Solak specializes in hormone therapy for prostate cancer at Hisar Hospital Intercontinental, with a background from prestigious institutions like Hacettepe University and MD Anderson Cancer Center.

• Trained at Hacettepe University Cancer Institute for oncology specialization
• Worked at The University of Texas MD Anderson Cancer Center
• Experienced in treating various cancers including prostate cancer
• Residency completed at Istanbul Sisli Etfal Training and Research Hospital

Professor Yesim Yildirim specializes in hormone therapy for prostate cancer at Anadolu Medical Center with 80+ international publications.

• Member of European Society of Medical Oncology (ESMO)
• Expert in cancer immunotherapy and targeted therapies
• Authored co-author in 'Handbook of Advanced Cancer Care Treatment'
• Professor at Halic University, Istanbul

Assoc. Prof. Dr. Heves Sürmeli is a specialist in Internal Medicine and Medical Oncology. She received her medical degree (M.D.) from Eskişehir Osmangazi University in 2004. She completed her Internal Medicine residency at Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul (2005–2010). She then completed subspecialty training in Medical Oncology at the same hospital (2014–2017).

At the same center, she served as a Medical Oncology Specialist (2017–2023). She then worked as Administrative and Clinical Director (2023–2026). Her clinical interests include breast, lung, gynecologic, gastrointestinal, and urologic cancers.

She has published many articles in international peer‑reviewed journals. She has presented at national and international conferences. She is active in professional societies. She has received several awards.

Dr. Eda Tanrikulu is a clinical oncologist at Anadolu Medical Center in Istanbul. She ranked 3rd nationally in Turkey's minor specialty medical exam. Dr. Tanrikulu specializes in chemotherapy and individualized cancer treatments. She works at a facility affiliated with the Johns Hopkins Hospital.

• Served as the head of the medical oncology unit at Haydarpaşa Numune Hospital.
• Participated in global training at Oxford University and ESMO in Manchester.
• Treats gastrointestinal, urological, lung, and breast cancers.
• Member of the American and European Societies of Medical Oncology.

Chief Physician at BKZ Solingen's certified cancer center – Phd Viola Fox leads innovative hormone therapy programs for prostate cancer.

• Specialized in chemotherapy, immunotherapy, and targeted therapies
• Qualified specialist in genetics with molecular diagnostics expertise
• Active researcher in haemato-oncological disease treatments
• Member of German and American oncology societies

Associate Professor specializing in breast, lung, and gastrointestinal cancers – Dr. Ozatli brings advanced expertise to hormone therapy for prostate cancer at Istinye Liv University Hospital.

• Internal Medicine Specialist with experience across multiple oncology departments
• Promoted to Associate Professor in 2016
• Works at a leading university hospital in Turkey

Dr. Mariam Abu Zeid is a clinical oncologist at Shefaa Al Orman International Oncology Hospitals. She is certified by the European Society for Medical Oncology. Dr. Abu Zeid treats solid tumors and hematologic cancers. She holds a Ph.D. in Clinical Oncology and Nuclear Medicine from Ain Shams University.

• Administers chemotherapy, immunotherapy, and targeted treatments for various cancer types.
• Oversees oncology clinical trials and manages treatment-related toxicities.
• Coordinates patient care within multidisciplinary teams for complex staging and diagnosis.
• Practices at an ESMO-accredited center that treats approximately 6,000 patients annually.

Associate Professor Muhammed Mustafa Atci specializes in hormone therapy for prostate cancer at İstinye University Liv Hospital Topkapı, combining clinical expertise with academic leadership.

• Board-certified in medical oncology with a focus on prostate cancer treatments
• Active member of the American Society of Clinical Oncology (ASCO)
• Published multiple peer-reviewed studies on cancer treatment outcomes
• Education Coordinator for Medical Oncology at Prof. Dr. Cemil Taşcıoğlu City Hospital

Professor of Medical Oncology with over 29 years of experience of experience – Dr. Cicin specializes in hormone therapy for prostate cancer at İstinye University Liv Hospital Topkapı.

• Fellowship-trained in Medical Oncology at Trakya University
• Former Associate Professor at Trakya University Faculty of Medicine
• Member of the Turkish Medical Oncology Association